This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC

369 views
September 20, 2024

Chapters

Introduction & Presentation Overview

00:00

First-Line Immunotherapy in HCC

00:36

HIMALAYA Trial & STRIDE Regimen Results

02:47

CheckMate 9DW Trial Insights

05:33

Selecting First-Line Therapy & Biomarkers

08:20

Sequencing After Immunotherapy

11:57

Treating Special Populations

16:25

Conclusions & Future Perspectives

17:10

Comments 0
Login to view comments. Click here to Login